Background {#Sec1}
==========

Advanced or metastatic breast cancer (MBC) typically has a negative impact on health-related quality of life (HRQoL). Patients may experience pain and other physical symptoms due to increasing tumor burden and metastases \[[@CR1]\], and some may develop depression or anxiety related to the diagnosis, treatments, concerns about the future, and body image \[[@CR2], [@CR3]\]. In addition, adverse events (AEs) related to MBC treatments can negatively affect HRQoL \[[@CR2]\].

Because available treatments for MBC are palliative rather than curative, preserving HRQoL is an important aspect of treatment selection, along with measures such as reducing tumor burden and prolonging progression-free survival (PFS) \[[@CR2], [@CR4]\]. Thus, evaluation of HRQoL outcomes is particularly relevant in studies of MBC therapies.

Eribulin mesylate, a nontaxane microtubule dynamics inhibitor \[[@CR5]\], has demonstrated an overall survival benefit relative to other commonly used agents in patients who have received ≥2 prior MBC therapies, including an anthracycline and taxane \[[@CR6]\]. In a randomized, open-label, phase 3 study that compared eribulin with capecitabine for MBC treatment in women who had previously been treated with anthracyclines and taxanes \[[@CR7]\], HRQoL was assessed using the European Organization for Research and Treatment of Cancer (EORTC) quality-of-life (QoL) (QLQ-C30) assessment tool \[[@CR8]\] and the Quality-of-Life Questionnaire for Breast Cancer (QLQ-BR23) \[[@CR9]\]. Scores for global health status (GHS)/QoL improved in both arms, with greater improvements in mean score for eribulin (13.5) than for capecitabine therapy (8.3). No significant differences were observed between the 2 groups, according to a linear mixed model (estimated treatment effect − 0.068, *P* = 0.958) and pattern-mixture model (estimated treatment effect 0.082, *P* = 0.949) \[[@CR7]\].

Trastuzumab is a human epidermal growth factor receptor 2 (HER2)-targeted humanized monoclonal antibody; previous clinical data have shown that the addition of trastuzumab to chemotherapy significantly improved overall survival, PFS, and disease-free survival relative to the use of chemotherapy alone in patients with HER2-positive (HER2+) MBC \[[@CR10], [@CR11]\]. Studies of trastuzumab, as monotherapy or in combination with chemotherapy, have also demonstrated a beneficial effect on HRQoL in patients with HER2+ MBC \[[@CR12]\].

Recently, 2 phase 2 trials evaluating the use of eribulin ± trastuzumab as first-line therapy in locally recurrent or MBC were conducted. Eribulin monotherapy in patients with HER2-negative (HER2-) breast cancer (Study 206) \[[@CR13]\] demonstrated an objective response rate (ORR) of 28.6%, overall clinical benefit rate (CBR) of 51.8%, and PFS of 6.8 months. Combination therapy of eribulin plus trastuzumab as first-line therapy in patients with HER2+ breast cancer (Study 208) \[[@CR14]\] showed an ORR of 71.2%, CBR of 84.6%, and PFS of 11.6 months. The present secondary analysis was conducted to assess the HRQoL results from the first 6 treatment cycles of these phase 2 trials of eribulin ± trastuzumab as first-line therapy for locally recurrent or MBC.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

These phase 2 studies were originally conducted to explore the antitumor activity and safety of eribulin monotherapy as first-line therapy in patients with locally recurrent or metastatic HER2- breast cancer (Study 206), and in combination with trastuzumab for patients with HER2+ breast cancer (Study 208). After completing 6  cycles of therapy in the treatment phase, patients were eligible to enter an extension phase in which they continued treatment until disease progression. Full details of the study designs have been published \[[@CR13], [@CR14]\]. Patient eligibility, study treatments, and study end points are shown in Fig. [1](#Fig1){ref-type="fig"}. Both studies were conducted in accordance with the Declaration of Helsinki (2008), and the protocol and informed consent forms were submitted for approval to institutional review boards. All patients provided written informed consent.Fig. 1Studies 206 and 208 designs

HRQoL assessments {#Sec4}
-----------------

HRQoL was assessed using the EORTC QLQ-C30 and QLQ-BR23 at baseline and day 1 of every other cycle (eg, C2D1, C4D1, C6D1) during both the treatment and extension phases. Designed with multi- and single-item scales, the QLQ-C30 is a 30-item questionnaire assessing function and symptoms that impact QoL in patients with cancer \[[@CR8]\]. It was developed as an integrated measurement system for international clinical trials and incorporates 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea and vomiting), and 1 global health and QoL scale. Several single-item measures assess common cancer symptoms (eg, dyspnea, loss of appetite, sleep disturbance, constipation, and diarrhea) and the perceived financial impact of cancer and its treatments \[[@CR8]\]. The QLQ-BR23 is a breast cancer-specific 23-item questionnaire that was designed to be used in conjunction with the QLQ-C30 to evaluate HRQoL in international clinical trials. It incorporates 2 functional scales (body image and sexuality), 3 symptom scales (arm symptoms, breast symptoms, and systemic-therapy side effects), and single items on sexual enjoyment, hair loss, and future perspective \[[@CR9]\].

Statistical analysis {#Sec5}
--------------------

Completion rates, scores, and summary statistics for the QLQ-C30 and QLQ-BR23 questionnaires were summarized at each assessment time point. An HRQoL form was considered complete if the patient answered at least 1 question. Clinically meaningful changes from baseline for each of the QLQ-C30 and QLQ-BR23 domains and single items were summarized at each time point. Percentages of patients in the "improved," "stable," or "worsened" categories were calculated based on a minimum important difference of ±10 points. For global health status and functional scales (QLQ-C30 and QLQ-BR23), "improved" scores were defined as a ≥ 10-point increase from baseline and "worsened" was defined as a ≥ 10-point decrease from baseline. For Symptom scales/items (QLQ-C30 and QLQ-BR23), "improved" scores were defined as decreases from baseline ≥10 points and "worsened" was defined as a ≥ 10-point increase from baseline. The value of 10 was selected to define a clinically meaningful difference based on previous randomized clinical trials where it was most common to assume that 10 points was clinically significant \[[@CR15], [@CR16]\]. These data were analyzed for the overall population. To assess the clinical relevance of each HRQoL symptom scale, the Spearman's rank correlation coefficient between individual HRQoL symptom scores and their corresponding AE rates (number of events divided by duration from the first date of study medication to the date of discontinuation from treatment + 30 days) was calculated.

Results {#Sec6}
=======

Patients {#Sec7}
--------

Study 206 enrolled 56 patients and Study 208 enrolled 52 patients, and 32 (57.1%) and 45 (86.5%) patients completed 6  cycles of therapy, respectively. Reasons for discontinuation included disease progression (*n* = 18 and *n* = 3, respectively), AEs (*n* = 3 in both studies), and patient choice (*n* = 3 and *n* = 1, respectively). Most patients (76%) were Caucasian with a median age of 56 and 60 years, respectively. The median time from diagnosis was 2.7 and 2.1 years, respectively. The majority of patients had disease that was estrogen receptor- or progesterone receptor-positive, and with the most common metastatic sites were bone, liver, and lung (Table [1](#Tab1){ref-type="table"}).Table 1Baseline demographics and disease characteristicsCharacteristicStudy 206 (*N* = 56)Study 208 (*N* = 52)Age, years Median (range)56 (31, 85)60 (31, 81) Mean (SD)57 (11)59 (11)Female, n (%)56 (100)51 (98)Race, n (%) Caucasian42 (75)40 (77) Black or African American12 (21)11 (21) Asian1 (2)1 (2) Other^a^1 (2)0Ethnicity, n (%) Hispanic or Latino3 (5)5 (10) Not Hispanic or Latino53 (95)47 (90)Mean time from original diagnosis of breast cancer, years (SD)5 (6)3 (3)Diagnosis of malignant disease, n (%) Ductal adenocarcinoma42 (75)46 (89) Lobular adenocarcinoma3 (5)3 (6) Other11 (20)3 (6)ER/PR/HER2 status, n (%) ER+ or PR+44 (79)36 (69) ER- and PR-12 (21)15 (29) HER2+052 (100) HER2-56 (100)0Site of metastasis, n (%) Bone37 (66)19 (37) Liver25 (45)25 (48) Lung22 (39)24 (46) Skin5 (9)3 (6) Other35 (63)33 (64) Lymph node involvement only3 (5)4 (8)*ER* estrogen receptor, *HER* human epidermal growth factor receptor, *PR* progesterone receptor, *SD* standard deviation^a^Other race: Non-Caucasian Hispanic

Efficacy {#Sec8}
--------

The ORR in Study 206 was 28.6% (95% CI: 17.30, 42.21), and in Study 208, it was 71.2% (95% CI: 56.92, 82.87). Results for secondary efficacy outcomes included median PFS of 6.8 months (95% CI: 4.44, 7.59) and 11.6 months (95% CI: 9.13, 13.93); median time to response of 1.4  months (95% CI: 1.22, 2.66) and 1.3  months (95% CI: 1.22, 1.38); median duration of response of 5.8 months (95% CI: 4.67, 10.55) and 11.1 months (95% CI: 6.70, 17.77); and CBR (CR + PR + durable stable disease) of 51.8% (95% CI: 38.03, 65.34) and 84.6% (95% CI: 71.92, 93.12), for Studies 206 and 208, respectively. Additional efficacy results were previously published \[[@CR13], [@CR14]\].

HRQoL scores {#Sec9}
------------

The completion rate (ie, percentage of patients who completed at least 1 item) for the QLQ-C30 and QLQ-BR23 was 94% (30/32) in Study 206 and 98% (44/45) in Study 208 at cycle 6 among patients who remained in the studies.

Clinically meaningful changes {#Sec10}
-----------------------------

In both studies, most patients had improved HRQoL scores for QLQ-C30 at cycle 6 (Table [2](#Tab2){ref-type="table"}). At cycle 6, more patients in Study 206 had an improvement (increases from baseline ≥10 for GHS and functional scales; decreases from baseline ≥10 for symptom scales) from baseline for physical functioning, role functioning, emotional functioning, social functioning, fatigue, nausea and vomiting, pain, dyspnea, insomnia, and appetite loss than had a worsening. More patients experienced a worsening in GHS/QoL, cognitive functioning, constipation, diarrhea, and financial difficulties than had an improvement. In Study 208, more patients experienced an improvement from baseline for GHS/QoL, physical functioning, role functioning, emotional functioning, pain, insomnia, and financial difficulties than experienced a worsening. More patients experienced a worsening for cognitive functioning, social functioning, fatigue, nausea and vomiting, dyspnea, appetite loss, constipation, and diarrhea than experienced an improvement. Figure [2](#Fig2){ref-type="fig"}a and [2](#Fig2){ref-type="fig"}b display the proportion of patients whose QLQ-C30 scores were stable/improved at cycles 2, 4, and 6. Baseline QoL scores are summarized in Additional file [1](#MOESM1){ref-type="media"}: Table S1.Table 2Percentage of patients with improved, stable, or worsened QLQ-C30 scores from baseline at cycle 6Symptom/ScaleStudy 206Study 208nImproved (%)Stable (%)Worsened (%)nImproved (%)Stable (%)Worsened (%)GHS/QoL296.955.237.94429.552.318.2Physical functioning2931.044.824.14422.759.118.2Role functioning2948.334.517.24429.545.525.0Emotional functioning2931.048.320.74438.640.920.5Cognitive functioning296.944.848.34413.640.945.5Social functioning2934.544.820.74427.340.931.8Fatigue2955.217.227.64431.818.250.0Nausea and vomiting2927.655.217.24420.554.525.0Pain2951.727.620.74447.731.820.5Dyspnea2931.062.16.94427.343.229.5Insomnia2941.451.76.94436.436.427.3Appetite loss2924.155.220.74422.745.531.8Constipation2917.262.120.74425.043.231.8Diarrhea296.972.420.7449.165.925.0Financial difficulties2913.869.017.24429.550.020.5*GHS* global health status, *QoL* quality of lifeFor global health status and functional scales, improved scores are defined as increases from baseline ≥10; worsened is defined as decreases from baseline ≥10. For symptom scales/items, improved scores are defined as decreases from baseline ≥10; worsened is defined as increases from baseline ≥10Fig. 2Proportion of patients who maintained/improved HRQoL -- EORTC QLQ-C30 in Study 206 (**a**) and Study 208 (**b**), ITT population

Most patients had stable HRQoL scores for QLQ-BR23 at cycle 6 (Table [3](#Tab3){ref-type="table"}). At cycle 6, more patients in Study 206 had an improvement (increases from baseline ≥10 for GHS and functional scales; decreases from baseline ≥10 for symptom scales) for future perspective, breast symptoms, and arm symptoms than had a worsening, respectively. More patients experienced a worsening in body image, sexual functioning, systemic therapy side effects, and "upset by hair loss" scores than had improvement. In Study 208, more patients experienced an improvement from baseline for future perspective, breast symptoms, and arm symptoms than had a worsening, respectively. More patients experienced a worsening in body image, sexual functioning, sexual enjoyment, systemic therapy side effects, and "upset by hair loss" than had improvement. Figures [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"} display the proportion of patients whose QLQ-BR23 scores were stable/improved at cycles 2, 4, and 6.Table 3Percentage of patients with improved, stable, or worsened QLQ-BR23 scores from baseline at cycle 6Symptom/ScaleStudy 206Study 208nImproved (%)Stable (%)Worsened (%)nImproved (%)Stable (%)Worsened (%)Body image^a^306.750.043.34418.254.527.3Sexual functioning^a^2810.764.325.0387.963.228.9Sexual enjoyment^a^201000911.166.722.2Future perspective^a^2722.259.318.54440.943.215.9Systemic therapy SEs^b^303.353.343.3444.545.550.0Breast symptoms^b^2623.161.515.44431.868.20Arm symptoms^b^2846.435.717.94447.729.522.7Upset by hair loss^b^2050.050.02050.050.0*QLQ-BR23* Quality-of-Life Questionnaire for Breast Cancer, *SE* side effect^a^For global health status and functional scales, improved scores are defined as increases from baseline ≥10; worsened is defined as decreases from baseline ≥10^b^For symptom scales/items, Improved scores are defined as decreases from baseline ≥10; worsened is defined as increases from baseline ≥10Fig. 3Proportion of patients who maintained/improved HRQoL---EORTC QLQ-BR23 in Study 206 (**a**) and Study 208 (**b**), ITT population

For both studies, changes in outcomes were also assessed in relation to treatment response, but because of the small number of patients following stratification by response, the data were insufficiently robust enough to allow for meaningful interpretations. However, the data were generally consistent with the overall observation that scores remained stable or improved for a majority of patients during treatment.

Correlation with adverse events {#Sec11}
-------------------------------

The most common treatment-related AEs (TRAEs) of any grade (incidence ≥25%) in Study 206 \[[@CR13]\] were alopecia (83.9%), neutropenia (71.4%), fatigue (60.7%), nausea (48.2%), peripheral neuropathy (44.6%), anemia (35.7%), leukopenia (33.9%), constipation (26.8%), and diarrhea (25.0%). Grade 3 or 4 TRAEs occurred in 36 patients (64.3%), with the most common being neutropenia (50.0%), peripheral neuropathy (19.6%), and leukopenia (21.4%). In Study 208 \[[@CR14]\], common TRAEs of any grade included alopecia (86.5%), fatigue (57.7%), peripheral neuropathy (59.6%), neutropenia (59.6%), nausea (36.5%), and anemia (25%). Grade 3 or 4 TRAEs occurred in 31 patients (59.6%), with the most common being neutropenia (38.5%) and peripheral neuropathy (21.2%). Mean symptom scales were significantly correlated with corresponding AE rates (nausea and vomiting, dyspnea, appetite loss, constipation, and diarrhea for Study 206; fatigue, nausea/vomiting, pain, dyspnea, insomnia, constipation, and diarrhea for Study 208. The only QLQ-BR23 item with a corresponding AE was "upset by hair loss," which was not significantly correlated in either study (Table [4](#Tab4){ref-type="table"}).Table 4Correlation between HRQoL symptoms and selected adverse eventsSymptom/ScaleStudy 206 (*N* = 56)Study 208 (*N* = 52)Spearman Correlation Coefficient (95% CI)*P* ValueSpearman Correlation Coefficient (95% CI)*P* ValueQLQ-C30 Fatigue0.14 (−0.13, 0.39)0.30590.31 (0.03, 0.53)0.0260 Nausea and vomiting0.33 (0.07, 0.55)0.01170.50 (0.26, 0.68)0.0001 Pain0.13 (−0.14, 0.37)0.35860.41 (0.15, 0.61)0.0025 Dyspnea0.31 (0.05, 0.53)0.02010.49 (0.25, 0.67)0.0002 Insomnia0.24 (−0.03, 0.47)0.08090.35 (0.08, 0.57)0.0104 Appetite loss0.35 (0.09, 0.56)0.00800.23 (−0.05, 0.47)0.1055 Constipation0.31 (0.05, 0.53)0.01910.30 (0.03, 0.53)0.0283 Diarrhea0.54 (0.32, 0.70)\< 0.00010.40 (0.14, 0.60)0.0032QLQ-BR23 Upset by hair loss^a^0.16 (−0.11, 0.41)0.23450.04 (−0.24, 0.31)0.8026*CI* confidence interval, *HRQoL* health-related quality of life, *QLQ-C30* Quality-of-Life Questionnaire for Patients with Cancer, *QLQ-BR23* Quality-of-Life Questionnaire for Breast Cancer^a^*n* ≤ 10 at each visit

Discussion {#Sec12}
==========

In these phase 2 studies, eribulin mesylate ± trastuzumab was evaluated as first-line therapy for locally recurrent or MBC. After 6  cycles, treatment did not lead to deterioration of overall HRQoL in most patients, with more than 60% of patients having stable/improved EORTC QLQ-C30 GHS/QoL scores. Minor differences were observed between the 2 trials, mainly in overall QOL with preservation over time in Study 208 and some deterioration in Study 206. Patients with stable/improved scores for the other items ranged from 51.7 to 93.2% in the QLQ-C30 and 50.0 to 100.0% in the QLQ-BR23 questionnaire. Most patients in both studies experienced improved pain (51.7 and 47.7%) and arm symptom scores (46.4 and 47.7%) with first-line eribulin, while most also had worsened cognitive functioning (48.3 and 45.5%). In Study 208, most patients also experienced worsened systemic therapy side effects (50%).

Significant correlations were observed between some of the most commonly reported AEs (fatigue, nausea and vomiting, pain, dyspnea, insomnia, constipation, and diarrhea) and corresponding HRQoL symptom items. Alopecia was a notable exception, due to a very limited number of responses for that item (*n* = 2 at cycle 6 for both studies). These correlations demonstrate consistency between investigator-reported adverse events and patient-reported outcomes.

It should be noted that as patients discontinued from the study, fewer patients were available for certain HRQoL assessments. For the scale of "upset by hair loss," fewer than 10 patients for each timepoint and each visit were available. For the scale of "sexual enjoyment," fewer than 10 patients for each time and each visit were available, with the exception of cycle 2 in which there were 11 patients. Similarly, the relatively small subgroups of responders and nonresponders hinder the ability to draw any conclusions regarding differences in HRQoL outcomes as a function of efficacy, or to evaluate whether HRQoL was a significant predictor of response as has been shown in other studies \[[@CR17]--[@CR20]\]. A larger patient sample would help to better demonstrate the effects of eribulin ± trastuzumab on these and other aspects of HRQoL.

While combination chemotherapy for MBC provides higher ORR, longer times to progression, and a modest survival benefit, it is also associated with increased toxicity \[[@CR21]\]. A systematic review published in 2005 \[[@CR21]\] that compared the use of single-agent chemotherapy with combination chemotherapy for MBC analyzed 9 trials that evaluated QoL, only 4 of which found statistically significant differences. Of the 4 trials, 2 (Heidemann et al. \[[@CR22]\] and Joensuu et al. \[[@CR23]\]) found improved QoL with single-agent therapy. Heidemann et al. used Brunner's score to assess QoL \[[@CR24]\] and found that single-agent therapy with mitoxantrone resulted in improved QoL scores for hair loss, nausea, and vomiting compared with combination chemotherapy. Joensuu et al. utilized the Rotterdam Symptom Checklist \[[@CR25]\] and found improved QoL scores for physical distress and nausea with epirubicin therapy compared with combination therapy. The remaining 2 studies (Nabholtz et al. \[[@CR26]\] and Simes et al. \[[@CR27]\]) reported mixed results. Using the EORTC QLQ-C30 questionnaire \[[@CR21]\], Nabholtz et al. \[[@CR26]\] reported that patients who received single-agent docetaxel experienced improved QoL scores for nausea/vomiting and loss of appetite while patients who received mitomycin and vincristine experienced improved QoL scores for role functioning and social functioning. Simes et al. \[[@CR27]\] reported improved QoL scores using the Spitzer QoL index \[[@CR28]\] during the first 3 months for pain, mood, and nausea and vomiting in the combination therapy group, but decreased QoL scores for hair loss compared with mitoxantrone monotherapy \[[@CR21]\]. A subsequent systematic review and meta-analysis of combination versus sequential single-agent therapies reported no significant difference in QoL, although only 3 of the 12 included trials reported on QoL \[[@CR29]\].

The results from Study 208 are generally consistent with those from a study of trastuzumab in combination with chemotherapy for HER2+ MBC, which also utilized the EORTC-QLQ-30 \[[@CR30]\]. In that study, patients treated with trastuzumab plus anthracycline/cyclophosphamide or paclitaxel chemotherapy (*n* = 208) and patients treated with chemotherapy alone (*n* = 192) had an initial worsening in fatigue, physical functioning, role functioning, social functioning, and global QoL at week 8 during treatment; patients in the trastuzumab plus chemotherapy group generally showed greater improvements in these domains following cessation of chemotherapy at week 20, with a statistically significantly greater improvement in fatigue at 32 weeks (*P* \< 0.05). In addition, the percentage of patients with improvement ≥10 points in global QoL was significantly greater among patients who received trastuzumab plus chemotherapy (51%) compared with the percentage among patients who received chemotherapy alone (36%; *P* \< 0.05 after Bonferroni correction) \[[@CR30]\]. In the CLEOPATRA study, HRQoL was evaluated using the Trial Outcome Index-Physical/Functional/Breast (TOI-PFB) of the Functional Assessment of Cancer Therapy-Breast (FACT-B) \[[@CR31]\]. In that study, patients (*n* = 806) treated with trastuzumab plus docetaxel (with or without pertuzumab) showed an initial decline in mean QoL scores during the first 6  cycles, which then returned to baseline; the median time to deterioration was approximately 18 weeks \[[@CR31]\]. The timing of the decline in TOI-PFB scores relative to the timing of docetaxel discontinuation suggested that AEs associated with docetaxel may have been a factor \[[@CR31]\]. In the AVEREL study, which assessed HRQoL using the FACT-B scale, mean scores among patients treated with docetaxel and trastuzumab (*n* = 174) decreased throughout the first 5 cycles, then increased at cycle 11, showing slight improvement over baseline; mean scores among patients who also received bevacizumab (*n* = 185) remained relatively stable through cycle 5, then increased at cycle 11 \[[@CR32]\]. In a study that compared trastuzumab plus docetaxel (*n* = 70) with trastuzumab emtansine (*n* = 67), the median time to decrease of 5 or more points on the FACT-B TOI-PFB was 3.5 months in the trastuzumab plus docetaxel group and was 7.5 months in the trastuzumab--emtansine group (*P* = 0.022) \[[@CR33]\].

Conclusions {#Sec13}
===========

The results of this secondary analysis of two phase 2 trials demonstrate that most patients experience stable or improved HRQoL scores when receiving eribulin mesylate ± trastuzumab as first-line therapy for locally recurrent or MBC. However, there were some exceptions; more patients experienced a worsening in cognitive functioning and systemic therapy side effects than experienced an improvement.

Efficacy data from these phase 2 trials also demonstrate that response rates with eribulin monotherapy are in line with what has been observed in trials of single-agent anthracyclines or taxanes in a similar treatment setting, and combination therapy with trastuzumab yields similar results as in previous studies \[[@CR30]--[@CR33]\]. Tolerability profiles and maintenance of symptom control were favorable and consistent with previous studies \[[@CR13], [@CR14]\]. Therefore, further evaluation is warranted to determine whether eribulin ± trastuzumab therapy may be a potential option for first-line treatment for some patients with metastatic breast cancer who were recently treated in the neoadjuvant setting.

Additional file
===============

 {#Sec14}

Additional file 1:**Table S1.** Summary of QLQ-C30 and QLQ-BR23 Baseline Scores. (DOCX 16 kb)
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